Disclosed are 1-aryl-[1,2,4]triazolo[4,3-a]quinoxaline derivatives as represented by the general formula (I), or a pharmaceutically acceptable salt thereof wherein: R1 represents an ortho-substituted phenyl or pyridyl ring R2 represents hydrogen or optionally substituted alkyl R3, R4, R5 and R6 are independently selected from hydrogen, halogen, optionally substituted alkyl, optionally substituted cycloalkyl, cyano, hydroxy, optionally substituted alkoxy or optionally substituted cycloalkoxy, and wherein the remaining substituents are as defined herein. Representative compounds include 8-chloro-1-(2-chloro-phenyl)-4-methyl-[1,2,4]triazolo[4,3-a]quinoxaline, 8-chloro-4-methyl-1-o-tolyl-[1,2,4]triazolo[4,3-a]quinoxaline, 8-chloro-1-(2-methoxy-phenyl)-4-methyl-[1,2,4]triazolo[4,3-a]quinoxaline, 8-chloro-1-(2,5-dichlorophenyl)-4-methyl-[1,2,4]triazolo[4,3-a]quinoxaline, 8-chloro-1-(2-chloro-5-methoxy-phenyl)-4-methyl-[1,2,4]triazolo[4,3-a]quinoxaline, 7-chloro-1-(2,6-difluorophenyl)-4-methyl-[1,2,4]triazolo[4,3-a]quinoxaline, 1-(2-chloro-phenyl)-4-methyl-[1,2,4]triazolo[4,3-a]quinoxaline, 1-(2-chloro-6-fluoro-phenyl)-4-methyl-[1,2,4]triazolo[4,3-a]quinoxaline, 4-methyl-3-(4-methyl-[1,2,4]triazolo[4,3-a]quinoxalin-1-yl)-phenol, 4-chloro-3-(4-methyl-[1,2,4]triazolo[4,3-a]quinoxalin-1-yl)-phenol, 1-(2-chloro-phenyl)-8-fluoro-4-methyl-[1,2,4]triazolo[4,3-a]quinoxaline, 1-(2-chloro-phenyl)-4-methyl-8-trifluoromethyl-[1,2,4]triazolo[4,3-a]quinoxaline, 1-(2,6-difluoro-phenyl)-4-methyl-7-trifluoromethyl-[1,2,4]triazolo[4,3-a]quinoxaline, 1-(2-chloro-phenyl)-7-methoxy-4-methyl-[1,2,4]triazolo[4,3-a]quinoxaline, 1-(2-chloro-phenyl)-7-[2-(3,4-dimethoxy-phenyl)-ethoxy]-4-methyl-[1,2,4]triazolo[4,3-a]quinoxaline, 1-(2-chlorophenyl)-4-methyl-8-(quinolin-2-ylmethoxy)-[1,2,4]triazolo[4,3-a]quinoxaline, 8-bromo-1-(2-chlorophenyl)-4-methy[1,2,4]triazolo[4,3-a]quinoxaline and 4-chloro-3-(8-chloro-4-methyl-[1,2,4]triazolo[4,3-a]quinoxalin-1-yl)phenol. Also disclosed is a medicament composit
